Limitations of the Patient Health Questionnaire-9 (PHQ-9)

Core Diagnostic Limitations

Assessment should not rely simply on symptom count alone—a phased screening and assessment approach is essential that incorporates pertinent history, risk factors, sociodemographic factors, psychiatric comorbidities, and duration of symptoms 1, 2, 3
False-positive rates reach 60-76% in primary care settings where depression prevalence is 5-10%, meaning the majority of positive screens do not represent true major depressive disorder 4

Some clinicians omit item 9 entirely, which artificially lowers scores and causes patients to appear less symptomatic than they actually are, while also weakening predictive validity and clarity of cutoff scores 1, 2, 3
The frequency and specificity of self-harm thoughts matter more than simple endorsement, but the PHQ-9 cannot capture these critical nuances 1, 2, 3

Differences in item functioning exist between language versions—the English and Chinese versions show discrepancies in assessing appetite, sleep, and psychomotor changes 5, 6
The English and French versions differ in assessment of sleep, self-esteem, and anhedonia items 5, 6
Despite translation into over 70 languages, less is known about psychometric properties in low- and middle-income countries where validation may be insufficient 5, 6
Item functioning varies between racial groups—differences appear in items about low energy, sleep, and psychomotor changes between African Americans and non-Latinx Whites 5, 6
Depressive symptom presentations differ across cultural contexts, but the PHQ-9 may not adequately capture these variations 5, 6
Without proper cross-cultural validation, the accuracy of prevalence rates and symptom profiles cannot be ensured across linguistic, racial, and ethnic groups 5, 6

The traditional cutoff of ≥10 may not be optimal for all populations—cancer outpatients show better diagnostic accuracy at a cutoff of ≥8 1, 2, 3, 7

Screening without clear protocols for managing positive screens does not improve outcomes—the PHQ-9 should never be administered without established pathways for diagnostic evaluation and treatment 7
Using a two-stage approach (PHQ-2 followed by full PHQ-9) may miss cases of suicidality that would be detected by administering the full PHQ-9 initially 7
The 2-week timeframe may not capture episodic or fluctuating symptoms adequately 7
The instrument was validated as a periodic assessment tool, not a daily symptom tracker, limiting its utility for frequent monitoring 7